Celldex Therapeutics Announces Multiple Upcoming Presentations of Barzolvolimab Data at GA²LEN Global Urticaria Forum (GUF) 2022

Rhea-AI Summary

Celldex Therapeutics has announced presentations from its barzolvolimab development program at the 6th GA²LEN Global Urticaria Forum in Berlin, December 7-8, 2022. Key highlights include data from the Phase 1b cold urticaria cohorts at 1.5 mg/kg and 3.0 mg/kg. The first day features an oral presentation on cold urticaria responses to barzolvolimab. The second day features a poster on mast cell suppression and an encore oral presentation on chronic spontaneous urticaria effectiveness. A webcast conference call is scheduled for December 6 at 8:00 a.m. ET.

- Includes oral presentation for 1.5 mg/kg cold urticaria cohort -

- Company to host webcast conference call on Tuesday, December 6 at 8:00 am ET -

HAMPTON, N.J., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that multiple presentations from the barzolvolimab development program will be presented at the 6^th GA²LEN Global Urticaria Forum (GUF) being held December 7-8 in Berlin, Germany. Abstracts will be available on the meeting website on December 6^th.

Presentations at GUF 2022 are outlined below and include new data from both the Phase 1b 1.5 mg/kg cohort conducted in cold urticaria and long term follow data from the Phase 1b 3.0 mg/kg cohorts conducted in cold urticaria and symptomatic dermographism. The chronic spontaneous urticaria (CSU) and wound healing presentations are Encore presentations and do not include new data.

WEDNESDAY, December 7, 2022

• Oral: “Cold urticaria patients achieve complete response with 1.5 mg/kg barzolvolimab” - Session III: Urticaria treatments and predictors of response | 18:07-18:16 CET

THURSDAY, December 8, 2022

• Poster: “Barzolvolimab-induced response and mast cell suppression are durable and linked” | 10:00 to 11:10 CET
• ENCORE Oral: “Multi-dosed barzolvolimab is effective in chronic spontaneous urticaria” - Session IV: Treatment of urticaria | 09:05-09:14 CET
• ENCORE Poster: Mast cell reduction does not impair human cutaneous wound healing
  

Webcast and Conference Call
The Company will host a conference call/webcast to discuss the data at 8:00 a.m. ET on Tuesday, December 6. The event will be webcast live and can be accessed by going to the "Events & Presentations" page under the "Investors & Media” section of the Celldex Therapeutics website at www.celldex.com.

About Celldex Therapeutics, Inc.
Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer. Visit www.celldex.com.

Company Contact
Sarah Cavanaugh
Senior Vice President, Corporate Affairs & Administration
(508) 864-8337
scavanaugh@celldex.com

Patrick Till
Meru Advisors
(484) 788-8560
ptill@meru.com

FAQ

What is the significance of the Celldex Therapeutics presentation on December 7, 2022?

The presentation highlights new data on the effectiveness of barzolvolimab in treating cold urticaria, featuring a 1.5 mg/kg cohort.

When will Celldex Therapeutics hold its webcast conference call?

Celldex will host a webcast conference call on December 6, 2022, at 8:00 a.m. ET.

Where will the GA²LEN Global Urticaria Forum take place?

The GA²LEN Global Urticaria Forum will be held in Berlin, Germany, on December 7-8, 2022.

What are the highlights of the GUF 2022 presentations by Celldex?

Highlights include data from the Phase 1b cold urticaria cohorts and encore presentations on chronic spontaneous urticaria.

What can we expect from the December 8 presentations at the GUF?

Presentations include a poster on mast cell suppression and an encore on multi-dosed barzolvolimab's effectiveness in chronic spontaneous urticaria.